RXDX-106 Is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignancies

标题
RXDX-106 Is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignancies
作者
关键词
-
出版物
EUROPEAN JOURNAL OF CANCER
Volume 69, Issue -, Pages S28-S29
出版商
Elsevier BV
发表日期
2016-12-10
DOI
10.1016/s0959-8049(16)32665-x

向作者/读者发起求助以获取更多资源

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started